The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies

BACKGROUND: Reducing the severity of respiratory symptoms is a key goal in the treatment of chronic obstructive pulmonary disease (COPD). We evaluated the effect of aclidinium bromide 400 μg twice daily (BID) on respiratory symptoms, assessed using the Evaluating Respiratory Symptoms in COPD (E-RS(™...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Paul W., Leidy, Nancy K., Hareendran, Asha, Lamarca, Rosa, Chuecos, Ferran, Garcia Gil, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877996/
https://www.ncbi.nlm.nih.gov/pubmed/27215749
http://dx.doi.org/10.1186/s12931-016-0372-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877996/
https://www.ncbi.nlm.nih.gov/pubmed/27215749
http://dx.doi.org/10.1186/s12931-016-0372-1

Ejemplares similares